NOV 02, 2016 8:51 AM PDT

Mutation Allows Liver Cancer Cells to Escape Limbo

WRITTEN BY: Xuan Pham

Increasingly, doctors are recognizing the impact of genetic differences on disease and treatment outcomes. This realization is impetus behind so many genetic testing initiatives, all with the goal of customizing treatments for individuals. Now, genetic research into liver cancer revealed a specific mutation, and patients with this disease profile may benefit from 2 different types of drugs already available.
 
Liver cancer is the tenth most common cancer, affecting over 39,000 people every year. Of this, it’s estimated that over 27,000 deaths from liver cancer will occur this year alone, making it the fifth most common cause of cancer death in men.
 
"Liver cancer is a deadly disease," said Luca Tordella, a postdoctoral scientist at the Imperial College London, and the study’s first author. But because the disease is modulated by different factors, no single treatment is effective for everyone. In particular, Tordella said, “It's important to better classify patients into groups, according to their genes. One advance of personalised medicine is to understand which drug will work best on you, and which on me."
 
Tordella’s team searched through the DNA of 100 people with liver cancer. They zeroed in on genes involved with cell senescence – a state of cellular limbo that prevents cancer from forming.
 
In their quest, the team stumbled on a mutation in the Arid1b gene, which allows cancer cells to bypass the senescence checkpoint. In essence, the mutation lets cells leave limbo and go on dividing uncontrollably – the hallmark of cancer cell progression.
 


This mechanism of liver cancer progression is part of a bigger pathway known as the SWI/SNF complex. "Around 20% of patients with liver cancer have mutations on the genes encoding for components of the SWI/SNF complex. What we suggest is if we treat these people with drugs that target the degradation of nucleotides, they will respond," said Jesus Gil, the study’s senior author. "We plan to continue to research this in the lab to develop treatments to target liver cancer."
 
Importantly, this complex has been successfully targeted by other cancer drugs, namely gemcitabine. This chemotherapy drug has been used to treat non-small cell lung cancer, pancreatic cancer, bladder cancer, and breast cancer.
 

 

About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 02, 2022
Cancer
Prostate Cancer: What's in a Name?
MAY 02, 2022
Prostate Cancer: What's in a Name?
Hearing the word “cancer” could have a significant psychological impact on a patient waiting on a diagnosis. ...
MAY 10, 2022
Cardiology
Screen Time is Linked to Heart Disease and Cancer
MAY 10, 2022
Screen Time is Linked to Heart Disease and Cancer
Spending too much time in front of the TV or computer can lead to major health risks.
AUG 18, 2022
Cancer
Why are Men More Prone to Cancer than Women?
AUG 18, 2022
Why are Men More Prone to Cancer than Women?
The overall risk of developing cancer is about the same for men and women (40.2% and 38.5%, respectively).  However ...
SEP 28, 2022
Drug Discovery & Development
Impact of In Vivo Controls on Therapeutic Drug Development
SEP 28, 2022
Impact of In Vivo Controls on Therapeutic Drug Development
The significance of antibody based in vivo studies   For both research and therapeutic purposes, antibodies ca ...
SEP 21, 2022
Cancer
Technology for Monitoring Tumors in Pre-Clinical Studies
SEP 21, 2022
Technology for Monitoring Tumors in Pre-Clinical Studies
Pre-clinical modeling, often using laboratory mice, is essential in developing life-saving therapies to treat cancer and ...
OCT 06, 2022
Chemistry & Physics
2022 Nobel Prize in Chemistry
OCT 06, 2022
2022 Nobel Prize in Chemistry
It’s that time of year again! Three scientists, Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless, were a ...
Loading Comments...